initi coverag
proteostasi vertex led way initi ow pt
summari initi coverag proteostasi
overweight rate price target proteostasi develop
cftr modul therapi treatment cystic fibrosi cf view cf
one well-perceiv research indic believ vertex
open door develop cftr modul evidenc three approv
advanc pipelin howev see clear opportun proteostasi
carv good portion market make name cf
foundat european cystic fibrosi societi provid immens
amount resourc toward understand cf addit monetari
contribut foundat conduct extens survey total
patient eu number statist collect
patient help formul clear understand diseas
alethia young three approv cftr modul demonstr
clear efficaci improv lung function reduc sweat chlorid
well-establish endpoint cf strong correl seen vitro
cftr protein activ lung function improv import read
across proteostasi vertex demonstr result mani patient
multipl cf type extend infant inde sinc approv
drug number cf case increas seen lower death
rate greater median age surviv
 make pti billion-dollar valuat seen initi
result proteostasi mid-dos doublet
achiev statist signific sweat chlorid
point improv baselin point
treatment effect vs placebo day feel data
strong believ greater efficaci could seen high dose data
triplet includ data
amplifi uniqu cftr modul class proteostasi
believ put compani differenti advantag state even
market penetr model proteostasi could
gener sale billion
initi ow pt base after-tax risk-adjust cf
npv futur cash flow estim opportun worth million
model cash million lead us
valuat billion
disclosur section may found page
initi coverag
proteostasi
overweight rate
price target
initi coverag proteostasi pti overweight rate
month price target proteostasi develop cftr modul treatment cystic
fibrosi compani number on-going phase studi evalu doublet triplet
proprietari drug combin studi assess drug add-on therapi standard
care view cystic fibrosi well-understood diseas receiv magnitud
support multipl cf foundat believ vertex rate ow alethia young ignit
engin establish proof concept drug class three approv drug
outlook see proteostasi next signific cf player earli clinic evid
uniqu amplifi advantag compani
view cystic fibrosi one well understood diseas great
deal support cystic fibrosi foundat european cystic
research side mutat identifi preval rate
record thirti countri
demograph collect patient eu data
includ statist patient age age diagnosi death rate mutat
inde number cf patient increas
number death declin support new research
vertex pave way cystic fibrosi well decad worth
research cftr modul role play cystic fibrosi
three drug approv date one potenti kalydeco two
corrector combin kalydeco orkambi symdeko
data three drug led improv lung capac sweat
chlorid measur hallmark diseas
long-term result seen mani patient multipl cf genotyp
extend infant
initi result pti doublet mid-dos achiev statist
signific lung capac sweat chlorid measur
amplifi uniqu class proteostasi demonstr
addit efficaci ad top orkambi
even market penetr model proteostasi
could gener sale billion
next six month catalyst rich addit doublet result high-dos
initi in-hous triplet data
events/valu driver month
preliminari data combin data cf
vertex report phase triplet therapi data cf
report interim data symdeko cf
expect data high-dos cohort cf
announc data symdeko cf
vertex announc phase triplet therapi data cf
proteostasi pti biopharmaceut compani develop novel
therapeut treatment cystic fibrosi proteostasi pipelin consist first
gener amplifi third gener corrector first gener
potenti studi intern combin approach add-on exist
standard care medicin compani found becam public base
clinic background cystic fibrosi cf cystic fibrosi cf inherit diseas character
obstruct mucu accumul mostli lung chronic respiratori infect damag
respiratori digest genitourinari system exhibit cf caus mutat cystic
fibrosi transmembran conduct regul cftr gene affect proper transport regul
chlorid ion channel due dysfunct patient develop thick viscou mucu
inflamm clog mucu clearanc
problemat infect exacerb inflamm mucou product perpetu
devast diseas cycl thick sticki mucu build-up lung limit abil breath
mucu build-up pancrea prevent releas digest enzym prevent breakdown
food absorpt vital
exhibit cystic fibrosi sign symptom
devast cycl clinic patient develop excess mucou build-up variou organ often
identifi first lung initi symptom may includ salty-tast skin persist
cough frequent infect wheez poor growth stool greasi appear build-
thick increas bodi suscept bacteri infect aeruginosa
mayo clinic septemb cystic fibrosi retriev
bacteri colon trigger product pro-inflammatori mediat prostaglandin
leukotrien associ activ phase immun respons due
ineffect abil clear bacteria activ persist lead addit inflamm
mucou gener devast cycl diseas exhibit lead persist inflammatori
respons progress fibrosi ultim loss organ function
exhibit lung damag cycl due chronic infect aeruginosa
median age surviv increas year year year
confid interv number patient cystic fibrosi foundat
cff patient registri increas sinc number death declin
report death compar death report exhibit europ
report death made total
exhibit demograph mortal cf patient
surviv outcom dramat improv better understand diseas
evolv treatment paradigm target key featur diseas includ lifestyl
improv nutrit guidelin new medic improv lung transplant outcom
beyond medic procedur patient may wear inflat vest caus vibrat result
loosen thin mucu may also use nebul open airway thin
mucu exhibit pancreat enzym supplement may help nutrient absorpt
cftr dysfunct diagnosi cf caus potenti mutat cftr
approxim cf patient possess mutat common delet
least one allel accord cff patient registri patient
least one copi mutat exhibit addit patient
homozyg two copi mutat heterozyg one-copi
mutat exhibit addit patient regist europ similar rate
least one allel record exhibit given high frequenc
mutat includ genet screen test provid highest detect rate
remain mutat occur rapidli decreas preval european patient
mean patient age half patient younger year old addit
patient registri age exhibit accord cf foundat
cystic fibrosi patient diagnos age two estim approxim
cf patient combin
due myriad potenti mutat involv cftr dysfunct genet screen may sometim
inconclus yield result singl mutat mutat found cftr gene
case without genet confirm patient diagnos confirm clinic measur
exhibit common cftr mutat report
exhibit mutat report
mutat lead issu cystic fibrosi patient mutat broken
differ class base cftr pathway malfunct exampl patient
misfold cftr protein prevent protein move cell
surfac patient make approxim cf case patient
mutat cftr protein move cell surfac howev channel gate
open properli exhibit make roughli case malfunct may includ
faulti channel insuffici quantiti lack function cftr therefor differ medicin
combin approach may abl treat specif patient popul
sweat chlorid clinic cf individu salt reabsorpt significantli lower due lower
conduct ion sweat duct epithelium result cf patient demonstr abnorm
high sweat chlorid concentr make sweat test standard six-step
process collect sweat chlorid patient includ
wash dri skin
ad pilocarpin stimul sweat gland insert electrod creat mild
current gland
remov electrod chemic
place piec filter paper area skin electrod place
cover skin plastic bandag
remov filter paper cover sweat
paper place buffer determin concentr chlorid exhibit
percent predict forc expiratori volum second measur much air
person exhal forc breath test given assess lung function part
diagnos diseas cystic fibrosi chronic obstruct pulmonari diseas copd asthma
patient condit may exhal smaller amount test conduct via spirometri test
patient blow tube result measur predict valu compar
volum expect person similar age gender bodi size ethnic etc
vertex decad worth work chang cf treatment landscap
vertex cftr modul kalydeco orkambi symdeko vertex ow
cover alethia young led way approv therapi cystic fibrosi patient
compani three approv drug multipl addit drug number combin
approach clinic develop kalydeco ivacaftor orkambi lumacaftor/ivacaftor
symdeko tezacaftor/ivacaftor ivacaftor approv treat patient base mutat
associ differ cftr classif
kalydeco ivacaftor vertex help cystic fibrosi foundat
therapeut announc plan pursu clinic develop march vertex
quickli progress initi phase trial may initi proof concept studi
kalydeco first medicin approv treat underli caus cystic fibrosi januari
 juli eu decemb canada februari ireland juli
australia origin approv patient age six older least one copi
mutat cftr gene previous discuss known gate
mutat cftr protein creat move cell surfac open
healthi patient cftr protein resid surfac cell gate open close
allow transport chlorid ion situat water salt content well balanc
form thin mucu could aid trap bacteria exhibit left patient cystic
fibrosi cftr protein defect gate remain close longer period time
prevent chlorid ion pass caus imbal salt water
form thick mucu exhibit right
kalydeco cystic fibrosi transmembran conduct regul cftr potenti drug
work open cftr gate longer period allow chlorid ion pass
approv kalydeco base two phase studi strive
envis phase studi discov new england
journal medicin result strive patient age show mean absolut
improv lung function week vs placebo envis trial children
age kalydeco experienc mean absolut improv baselin lung function
week vs placebo vertex submit applic prioriti review approv
octob prioriti review grant decemb
vertex conduct addit phase label-expans studi target addit age
group relat mutat februari fda approv supplement nda
includ eight addit mutat cftr gene
approv announc vertex state eight
mutat present patient age six older mutat
approv eu juli account addit target patient age six older
eu
decemb kalydeco approv patient age six older
mutat cftr gene approv base result konduct
studi vertex believ patient age six older mutat march
vertex receiv fda approv kalydeco ten mutat children age
two five march compani believ children
mutat age two five vertex also introduc new weight-bas oral granul
formul kalydeco tablet granul formul mix either
soft foot liquid child swallow tablet europ approv kalydeco
patient age two five novemb along expand use kalydeco
includ patient age older mutat august fda approv
kalydeco ten total mutat patient month approv base
data arriv studi eu made approv octob addit
submiss expect infant age month
vertex initi receiv complet respons letter februari approv
kalydeco addit mutat patient two year older includ
kalydeco ultim approv mutat may
august compani believ made elig patient
orkambi lumacaftor/ivacaftor orkambi combin kalydeco
ivacaftor lumacaftor function ivacaftor previous discuss allow cftr
protein gate stay open longer allow re-bal chlorid ion lumacaftor corrector
design increas number cftr protein cell surfac exhibit
orkambi first approv fda juli eu novemb canada januari
australia march initi approv treat patient age older
two copi mutat vertex believ patient
patient eu patient australia two copi mutat
common genet form septemb januari fda european commiss
extend approv patient age six respect recent august fda
extend approv orkambi patient age two-fiv addit elig patient
vertex initi phase studi march announc result februari
base data demonstr statist signific declin sweat chlorid compani
decid initi combin studi kalydeco phase studi initi
month later octob interim data readout june show
reduct sweat chlorid final data report june show mean absolut
improv lung function within group improv vs
placebo homozyg patient receiv combin treatment
kalydeco day exhibit
day
lung function
day
mean absolut chang
alon qd
first day follow
addit kalydeco
day
alon qd
first day follow
day vs
result support phase studi initi februari vertex conduct two phase
studi traffic transport evalu qd
combin ivacaftor vs placebo result
trial provid june studi meet primari endpoint
mean absolut improv baselin vs placebo exhibit mean absolut
improv report baselin vs placebo
addit pool analysi show reduct vs rate pulmonari exacerb
combin vs placebo base data vertex submit nda
novemb fda advisori panel vote recommend approv may vertex
run phase studi children age month
report concern orkambi use evidenc extens list warn
precaut label includ observ elev transaminas alt/ast
associ elev bilirubin respiratori event includ chest discomfort drug interact
symdeko tezacaftor/ivacaftor ivacaftor april vertex cystic fibrosi
foundat announc collabor second corrector tezacaftor
symdeko approv patient two copi mutat least one
mutat respons tezacaftor//ivacaftor initi approv target patient age
older tezacaftor work bring cftr protein cell surfac ivacaftor increas
amount time protein gate stay open exhibit
initi phase safeti data show combin well toler mean rel increas lung
function seen two highest dose group versu
placebo result led vertex conduct two phase studi evolv expand evalu
combin ivacaftor peopl one two copi mutat
result announc march homozyg mutat patient mean absolut
improv compar placebo heterozyg patient mean
absolut improv compar placebo studi
combin treatment gener well toler common report
infect pulmonari exacerb cough exhibit result vertex submit nda
grant prioriti review fda symdeko third cystic fibrosi drug
vertex receiv approv februari vertex guid toward file snda
children age year-end
symdeko known symkevi eu vertex report posit chmp opinion peopl
age older drug receiv european market author novemb
approv indic patient age either two copi
mutat one copi mutat addit mutat residu activ
provid snapshot vertex pivot trial result exhibit
exhibit summari vertex drug mechan
beyond vertex three approv drug compani commit continu develop addit
drug cystic fibrosi exhibit discuss program greater depth
competit section report
exhibit summari vertex drug mechan
potenti allow cftr protein gate stay open longer
corrector design fix defect cftr protein move cell surfac
enac inhibitor work restor airway surfac liquid volum allow mucociliari
exhibit summari vertex commerci clinic program
one follow
copi
copi one mutat
expect respons
copi one mutat
expect respons
copi one mutat
expect respons
one copi mutat one minim function
mutat like respond drug
copi
one copi mutat one minim function
mutat like respond drug
copi
copi one mutat
like respond drug
copi one mutat
like respond drug
copi
mutat like respond drug
stage develop
month
proteostasi network pn proteostasi network pn compos pathway cellular
process control protein biosynthesi fold track clearanc within cell essenti
pn aid cell reach final destin correctli fold protein
effect pn imbal proteostasi network could lead diseas includ cystic
fibrosi inde pn cope misfold protein could lead exacerb
diseas state exhibit proteostasi develop therapi aim control rebalanc
pti cftr modul proteostasi suit cftr modul cystic fibrosi
includ amplifi corrector potenti compani envis
use drug add-on use proprietari in-hous combin potenti
ivacaftor work increas amount time cftr protein gate stay open corrector
lumacaftor tezacaftor design fix defect cftr protein move cell surfac
amplifi increas amount cftr protein cell exhibit understand
amplifi class uniqu proteostasi unawar compani pursu
develop one
add therapi
orkambi proteostasi ran trial cf subject year age
homozyg patient elig patient lung function
background orkmabi treatment least three month trial random
patient receiv four patient receiv placebo patient observ
day trial exhibit combin breakthrough therapi orphan drug
result trial announc decemb trial met efficaci endpoint pti-
orkmabi demonstr mean absolut improv mean rel
improv compar baselin day result achiev day
sustain day dose trial exhibit
addit result show patient posit rel chang
receiv orkambi vs patient placebo orkambi one subject
posit rel chang treatment arm compli
inhal antibiot treatment regimen specifi protocol exhibit
orkambi proteostasi conduct combin studi cf subject year age
homozyg patient elig patient lung function
take orkambi minimum three month patient random
patient receiv patient receiv patient receiv
patient receiv placebo lead-in period evalu patient
orkmabi combin dose day primari endpoint studi safeti
secondari outcom measur includ pk profil effect effect sweat chlorid
weight exhibit compani receiv track design
result studi announc june studi two patient cohort
discontinu subject decis constip prior dose one patient cohort
discontinu due pulmonari exacerb safeti mild moder includ
cough infect pulmonari exacerb cystic fibrosi chest discomfort headach dyspnea
exert difficulti breath result show ad affect orkambi
addit improv across differ cohort
statist signific exhibit result also demonstr improv sweat chlorid
baselin particularli evid dose cohort led improv
exhibit addit result dose cohort show
improv improv weight baselin
evid dose observ improv serum glucos level led
improv baselin diabet patient
symdeko proteostasi conduct studi cf patient year old
homozyg mutat lung function elig patient need
symdeko background treatment least one month trial random
activ placebo could enrol subject dose day exhibit initi
data expect earli
symdeko proteostasi conduct studi cf patient year old
homozyg mutat lung function elig patient need
symdeko background treatment least one month exhibit trial could enrol
cf subject evalu two dose vs placebo initi data expect earli
doublet proteostasi conduct combin doublet studi
homozyg cf patient elig patient year old lung
function patient take cftr modul therapi
primari endpoint trial safeti
secondari outcom measur includ measur pk profil sweat chlorid weight
proteostasi report initi data trial exclud highest dose octob regard
pk profil exposur level increas dose increas major mild
moder sever sae note pulmonari exacerb report
result dose demonstr statist signific
improv trial day point chang baselin
point treatment effect vs placebo day point chang
baselin point treatment effect vs placebo remind
treatment period end day declin observ day patient
cohort statist signific result achiev sweat chlorid improv
day point reduct baselin point reduct
treatment effect vs placebo day point reduct baselin
point reduct treatment effect vs placebo exhibit improv also
seen day day low dose cohort
triplet proteostasi evalu tripl combin
cf subject year age homozyg mutat
patient trial lung function take
cftr modul therapi exhibit protocol receiv endors high strateg fit
score develop network tdn clinic trial network ctn arm
cff european cf societi ecsf compani previous ran patient trial healthi
volunt led safeti pk profil achiev seven day daili dose
futur pivot trial proteostasi announc plan begin phase trial next month
time-frame understand proteostasi could run phase trial proprietari drug
pti ultim design could chosen full data set
observ doublet triplet
compani may also choos run pivot studi patient background vertex medic
may includ orkambi symdeko one triplet approv see drug work
exhibit summari pti drug potenti cf landscap
novemb proteostasi enter collabor astella pharma
cover term research develop commerci licens agreement
compani develop candid relat unfold protein respons upr pathway astella
purchas million convert promissori note proteostasi elig receiv research
fund support sale mileston payment million addit mid-single-digit
low double-digit royalti proteostasi option co-develop compound otherwis astella
exclus right
cystic fibrosi agent treatment cystic fibrosi commonli broken four
categori cftr-modul anti-mucolyt anti-inflammatori anti-infect therapi
addit treatment exist nutritional-gi compon therapi target specif patient
genet mutat accumul mucou lung reduct inflamm pulmonari
infect associ diseas respect patient requir rotat medic aim
treat variou aspect believ proteostasiss competitor
focus domain restor cftr function exhibit
exhibit cftr-restor drug clinic develop
beyond vertex suit approv drug compani pursu addit combin next-
gener compound februari vertex announc plan pursu pivot phase trial
next-gener corrector vertex guid toward submit nda
program phase data show improv across sweat chlorid cfq-r
drug homozyg heterozyg patient specif homozyg patient
show absolut increas
heterozyg patient absolut increas
exhibit result obtain day
tezacaftor ivacaftor previous discuss report vertex conduct two
phase trial tezacaftor ivacaftor studi evalu children age
twelv one trial evalu patient one copi mutat one
minim function mutat like respond drug deem min random double-
blind placebo-control studi could enrol patient receiv tripl combin therapi
tezacaftor ivacaftor ivacaftor pm
patient receiv placebo primari endpoint studi mean absolut chang lung function
baselin week secondari outcom measur includ number pulmonari exacerb
absolut chang sweat chlorid cfq-r score bodi weight week addit
potenti nda submiss could support data addit safeti data week
second trial evalu patient two copi mutat
random double-blind active-control studi could enrol patient receiv tripl
combin therapi tezacaftor ivacaftor ivacaftor
pm patient receiv placebo primari endpoint studi mean absolut chang
lung function baselin week secondari outcom measur includ chang cfq-r
sweat chlorid week addit potenti nda submiss could support
data addit safeti data week studi exhibit
triplet therapi trial fulli enrol phase data expect
tezacaftor ivacaftor vertex anoth triplet therapi develop
tezacaftor ivacaftor design similar triplet phase develop look two
separ trial children age first trial enrol patient
one copi mutat one minim function mutat like respond drug
random double-blind placebo-control studi enrol patient receiv tripl
combin therapi tezacaftor ivacaftor ivacaftor
pm patient receiv placebo primari endpoint studi mean absolut
chang lung function baselin week secondari outcom measur includ number
pulmonari exacerb absolut chang sweat chlorid cfq-r score bodi weight
week addit potenti nda submiss could built data addit
safeti data week exhibit
second trial evalu patient two copi mutat
tezacaftor ivacaftor tripl combin regimen trial initi april
random double-blind placebo-control studi could enrol patient receiv tripl
combin therapi tezacaftor ivacaftor ivacaftor
pm patient receiv placebo primari endpoint studi mean absolut chang
lung function baselin week secondari outcom measur includ chang cfq-r
sweat chlorid week addit potenti nda submiss could support
connect data addit safeti data week studi exhibit
enrol remain on-going studi phase data expect
octob vertex announc plan initi phase studi tezacaftor
ivacaftor four-week studi addit compani announc plan run phase studi
ivacaftor tezacaftor two-week studi trial enrol patient one
copi mutat minim function mutat patient two copi
mutat studi initi april
galapago glpg cover conduct phase
multi-cent open-label non-random multi-cohort falcon studi cf patient falcon
trial observ combin treatment includ
separ doublet trial part trial observ homozyg mutat patient
part observ homozyg heterozyg mutat patient exhibit
result part studi announc octob drug well toler
long-term safeti still on-going two-week treatment led mean
decreas baselin sweat chlorid mean increas
addit enhanc cftr activ ad equat safeti
follow-up take place time compani review full data make
decis whether initi part trial day announc galapago
announc cover obtain exclus world-wide right galapago
cf investig drug candid portfolio galapago receiv up-front payment million
elig receiv million addit mileston payment singl double-digit
eluforsen proqr therapeut prqr cover develop eluforsen
treatment cystic fibrosi eluforsen first-in-class rna-bas oligonucleotid target patient
mutat proqr licens technolog massachusett gener hospit
corpor present current list eluforsen pipelin program updat
made phase random doubl blind placebo-control dose escal trial conduct
primari endpoint safeti secondari outcom measur includ chang
cfq-r respiratori symptom score bodi weight sweat chlorid chang eluforsen
orphan drug eu track design
preliminari result report septemb led mean improv point compar
placebo cfq-r rss measur improv seen multipl dose group
furthermor improv point vs placebo observ predefin subgroup
subject lower lung function baselin improv lung function
observ multipl dose group measur absolut chang ppfev versu placebo
pre-defin subgroup improv compar placebo exhibit drug
safe well toler seriou advers event relat treatment report uncertain
whether proqr continu develop eluforsen
addit compani target cftr modul therapi earlier develop
summar competit landscap trial exhibit
beyond cftr function restor number compani pursu treatment differ
mechan includ mucociliari clearanc work help break mucu lung anti-
inflammatori work dampen immun respons without affect natur defens anti-
infect given cf patient prone infect airway clog nutritional-gi-
relat drug relat diseas caus complic believ drug could work well
combin approach cftr modul treat entireti diseas
price market potenti
kalydeco previous discuss kalydeco given oral tablet packet use
children drug sold patient roughli pound daili dose
patient pound children adult kalydeco taken everi hour
compani stress take twice day kalydeco drug come
cours treatment suppli oral tablet packet wac per
day suppli translat per cantor model net kalydeco
price row price price outsid may fluctuat per
countri vertex drug drug taken fat-contain food
orkambi kalydeco orkambi given either oral tablet packet everi twelv
hour also like kalydeco orkambi taken food contain high amount
fat children age patient take two tablet everi hour four total daili dose lumacaftor
ivacaftor patient older two tablet taken everi hour four total
daili dose lumacaftor ivacaftor patient pound receiv one
packet everi twelv hour two packet per day lumacaftor ivacaftor patient
pound receiv one packet everi twelv hour two packet per day lumacaftor
ivacaftor oral tablet packet wac suppli lead
cost per year cantor model net price ex-u
symdeko given recent approv symdeko current approv patient year
old sold tablet form symdeko also taken everi twelv hour fat contain
food first pill contain tezacaftor ivacaftor second pill contain
ivacaftor suppli wac equat annual price
cantor current model net price eu
translat blockbust sale vertex produc blockbust sale suit cystic
fibrosi drug approv year date septemb three drug combin led
sale billion roughli line report total sale kalydeco
orkambi exhibit
note kalydeco approv januari orkambi approv juli
symdeko approv februari
file cantor fitzgerald research
model util price assumpt eu per patient per year
estim launch price take account drug orphan design
diseas patient popul approxim net price
current approv cftr therapi rang cystic fibrosi
foundat report list patient cf least one mutat
european cystic fibrosi societi patient registri list patient regist cf
least one allel record believ signific
pressur price exhibit
estim market peak penetr achiev within eight year anticip
approv estim combin eu sale billion reach
peak market penetr given understand cftr modul pave vertex initi
clinic data ascrib probabl success exhibit
model current account pti proprietari hous formula doublet triplet also
yet model potenti pti sell intern drug add-on therapi exist medicin
exhibit cystic fibrosi market model proteostasi therapeuticsnasdaqg pticyst fibrosi cystic fibrosi patient receiv pti product sale expens probabl ebt discount fibrosi foundat cff patient registri cff patient registri annual data reportsourc cantor fitzgerald estim
exhibit cystic fibrosi market model therapeuticsnasdaqg pticyst fibrosi market cystic fibrosi patient receiv pti sale expens probabl ebt discount cystic fibrosi societi patient registri annual data report cystic fibrosi societi patient registri annual data report cantor fitzgerald estim
exhibit npv modelproteostasi therapeuticsnasdaqg ptinpv model fibrosi fibrosi product probability-adjust share probability-adjust tax earn taxessourc cantor fitzgerald estim novemb
proteostasi experienc manag team summar
meenu chhabra presid chief execut offic
ms chhabra serv presid chief execut offic member board
director sinc may august may ms chhabra presid chief
execut offic allozyn inc biopharmaceut compani decemb august
serv vice presid busi develop licens novarti
pharmaceut divis novarti ag nyse nv juli novemb
serv chief busi offic bioxel spa spin-off hoffmann-laroch ltd milan
research institut itali led corpor develop financ activ ms chhabra
also held manag posit freseniu kabi ag warner-lambert compani llc
bristol-my squibb compani nyse obtain york univers
 sc univers toronto
dr zecev serv chief oper offic sinc februari serv
previous chief busi offic march februari vice presid busi
develop august march april juli serv founder
manag director zebra ventur srl firm provid busi develop consult
servic proteostasi august juli tenur manag director
also serv founder coordin industri liaison offic italian cystic
act head busi develop allozyn inc prior join
zebra ventur srl dr zecev serv busi develop manag bioxel spa
bxln octob march staff scientist march septemb
dr zecev receiv molecular biolog univers belgrad serbia ph
biochemistri institut physiolog univers zurich switzerland master
intern healthcar manag bocconi school manag milan itali
ms wilson serv senior vice presid clinic develop oper sinc
februari serv previous vice presid clinic oper sinc octob
prior join proteostasi therapeut ms wilson serv vice presid global oper
synta pharmaceut lexington massachusett juli februari ms wilson
head sheila wilson consult develop oper govern strategi clinic
qualiti consult standard oper procedur sop variou pharmaceut compani
ms wilson vice presid global clinic oper vertex pharmaceut inc
cambridg massachusett march novemb led global clinic
oper support phase iv clinic program ms wilson also serv senior vice
presid oper qualiti assur epharmasolut conshohocken pennsylvania
januari march respons creation administr
intern polici sop prior serv vice presid us medic oper
pharmaceut inc
dr serv execut vice presid sinc decemb chief medic offic
sinc may previous serv senior vice presid clinic develop may
decemb vice presid clinic develop novemb may
februari novemb serv translat medicin expert novarti
institut biomed research august januari dr serv associ
medic director vertex pharmaceut incorpor support
clinic develop registr kalydeco led cftr corrector program posit
proof-of-concept may august dr serv physician-scientist
brigham women hospital/harvard medic school receiv biolog
john hopkin univers univers pennsylvania
dr munoz serv chief scientif offic sinc march serv execut
vice presid drug discoveri septemb march previous dr munoz serv
senior vice presid drug discoveri decemb august vice presid
medicin chemistri novemb decemb februari novemb
serv director medicin chemistri molecular librari probe product center
network broad institut biomed research institut affili harvard univers
massachusett institut technolog role broad institut dr munoz
respons design implement phenotyp screen platform identifi activ
molecul within broad collect small molecul gener potent hit therapeut
potenti neglect diseas octob octob serv number
posit increas respons merck co nyse recent director
research laboratori merck co boston massachusett laboratori formerli serv
board karyopharm therapeut inc dr munoz receiv ph
organ chemistri univers toronto sc chemistri brock univers
also complet postdoctor train scripp research institut
dr gilmartin serv chief develop offic sinc august januari
august held posit increas respons astrazeneca plc nyse azn
recent serv senior medic lead global medicin develop benralizumab
phase program sever asthma januari januari held posit increas
respons vertex pharmaceut incorpor includ serv medic
lead kalydeco ivacaftor clinic develop program spearhead initi phase
trial support label expans studi drug addit leadership posit life
scienc industri dr gilmartin attend physician intens care unit beth israel
deaco medic center formerli serv director bidmc sleep disord center
pulmonari leadership team dr gilmartin receiv histori dartmouth colleg
brown univers school medicin master medic scienc clinic research
harvard medic school
financi perform outlook
proteostasi report cash cash equival balanc million june
proteostasi rais addit million octob compani guid
cash suffici run oper start phase trial month
arriv price target ad after-tax risk-adjust npv
futur cash flow proteostasi cystic fibrosi program current ascrib probabl
success cf program probability-adjust fulli tax npv discount
rate clinic program million ad cash
million lead us price target billion
proteostasi development-stag compani invest subject risk
risk includ limit
clinic risk proteostasi clinical-stag compani current commerci
product clinic trial fail compani may never commerci sale proteostasi
focus rare-diseas cystic fibrosi delay patient recruit enrol
push back sale estim significantli
regulatori risk drug develop compani proteostasi requir
approv regulatori agenc challeng face conserv fda stanc could
requir compani run addit clinic trial produc data caus
reimburs risk cf drug approv use proteostasi need seek
achiev reimburs variou entiti includ govern privat
public payer without reimburs proteostasi could fail gener revenu
financ risk cash posit proteostasi million june
includ addit financ million octob estim
compani burn approxim million next month proteostasi may
success rais addit fund favor term sustain futur
oper proteostasi requir addit financ run pivot trial cf drug
estim trial could potenti run differ combin studi could
commercial/competit risk signific market potenti demonstr vertex
attract number competitor treatment cystic fibrosi number
competit agent develop treatment cystic fibrosi vertex three
approv drug indic addit combin therapi late-stag
research develop
gener administr
loss oper
basic dilut loss per share
weight averag number share outstand
equival
account receiv accru incom
properti plant equip net
accru expens current liabil
current portion long-term debt
current portion defer rent
current portion defer revenu
current portion contig consider
total liabil stockhold equiti
valuat model attribut probabl success cystic fibrosi
probability-adjust fully-tax npv discount rate potenti cash flow
million per share includ estim ye cash million arriv
valuat billion share price target
compani report factset research cantor fitzgerald research
institutionsshar manag co associ fund invest vanguard group capit manag ltd hong invest advisor uk spring capit manag trust invest capit manag invest manag fund manag capit manag row price associ manag co co capit ventur partner model fibrosi fibrosi product probability-adjust share probability-adjust tax earn taxessourc cantor fitzgerald estimatescompani informationrec share outstand market cap total debt enterpris valu averag daili volum short interest day compani rais addit million octob novemb
proteostasi pti biopharmaceut compani develop novel therapeut treatment cystic
fibrosi proteostasi pipelin consist first gener amplifi third gener corrector first
gener potenti studi intern combin approach add-on exist standard care medicin
